Risk stratification for prediction of locoregional recurrence in patients with pathologic T1–2N0 breast cancer after mastectomy

Table 3 Significant prognostic factors for 5-year LRR by multivariate regression analyses

Variables	Multivariate analyses
	LRR
	HR	95%CI	p
1999–2007 vs. 2008–2014	1.923	1.380–2.688	< 0.001
Age ≤ 40 years old vs. > 40 years old	2.262	1.646–3.107	< 0.001
Inner location vs. Non-inner location	2.236	1.787–2.798	< 0.001
T2 stage vs. T1 stage	1.419	1.061–1.898	0.018
ER/PR (−) vs. ER and PR(+)	1.485	1.042–2.117	0.029
LVI vs. without LVI	1.053	0.879–1.262	0. 575
Grade III vs. Grade I and II	1.237	0.8861.726	0. 212
IDC vs. other pathology type	0.848	0.715–1.006	0.059
Adjuvant chemotherapy vs. non-adjuvant chemotherapy	1.429	0.951–2.147	0.086
Endocrine therapy vs. non- Endocrine therapy	0.728	0.524–1.012	0.059
Anti-Her2 target therapy vs. non- Anti-Her2 target therapy	0.606	0.246–1.492	0.276

ER Estrogen receptor, Her2 Human epidermal growth factor receptor 2, HR Hazard ratio, IDC Invasive ductal carcinoma, LRR Locoregional recurrence, LVI Lymphovascular invasion, PR Progesterone receptor

ISSN: 1471-2407